Loading...
Market
Major adverse effects reported for Asciminib (Scemblix) in US by October 2025?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
FDA announcements, Novartis press releases, or major medical journals
Story
FDA Grants Accelerated Approval for Novartis's Asciminib (Scemblix) for CML, 25% Major Molecular Response Rate
Oct 29, 2024, 05:35 PM
The U.S. Food and Drug Administration (FDA) has granted accelerated approval for Novartis's asciminib (brand name Scemblix) as a treatment for adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase. Clinical trials demonstrated a 25% major molecular response rate at 24 weeks for asciminib, compared to 13% for the previous standard treatment, bosutinib. This approval positions asciminib as a promising option for frontline therapy in this patient population. Further application reviews are ongoing with other regulatory agencies, including Health Canada.
View original story
Similar markets
No reports • 25%
Mild side effects • 25%
Moderate side effects • 25%
Severe side effects • 25%
Dry mouth • 25%
Drowsiness • 25%
Nausea • 25%
Other • 25%
Fatigue • 25%
Nausea • 25%
Rash • 25%
Other • 25%
Nausea • 25%
Fatigue • 25%
Diarrhea • 25%
Other • 25%
No serious side effects • 33%
Mild side effects • 33%
Severe side effects • 33%
Mild side effects • 25%
Moderate side effects • 25%
Severe side effects • 25%
No major side effects • 25%
Cytokine release syndrome (CRS) • 25%
Immune effector cell-associated neurotoxicity syndrome (ICANS) • 25%
Secondary cancers • 25%
Other • 25%
Yes • 50%
No • 50%
Mild side effects • 25%
Moderate side effects • 25%
Severe side effects • 25%
No significant side effects • 25%
SMA Type 3 • 25%
SMA Type 2 • 25%
Both SMA Type 2 and 3 • 25%
Other • 25%